Gilead to support generic lenacapavir in low-income nations
Earlier this month, Gilead Sciences announced that it had signed non-exclusive, royalty-free voluntary licensing agreements…
Posted inNews PrEP Prevention Research
Twice-yearly lenacapavir 89% more effective than Truvada
New data from the PURPOSE 2 study shows that twice-yearly lenacapavir is 89% more effective…